Ginkgo Bioworks Holdings, Inc.
NYSE:DNABiotechnology
+$0.26 today
- Market cap
- $547.12M
- Beta
- 1.80
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.11
Volume 2.36M
Average 1.24M
DNA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ginkgo Bioworks Holdings, Inc.NYSE: DNA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $49.92M fell 29.6% year over year, ahead of the -37.9% change in trailing-twelve-month research & development. Sequentially, it fell 0.4% from the prior quarter. Over 3 fiscal years it compounded at -38.6% a year.
Context
- Research & development amounted to 143.3% of revenue in FY2025, down 43.5 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -29.6% holds above the trailing-twelve-month pace of -37.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 243.77M USD
- Year-over-year change
- -42.5%
- 4-year CAGR
- -32.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 243.77M | -42.5% |
| FY2024 | 2024-12-31 | 424.06M | -27.0% |
| FY2023 | 2023-12-31 | 580.62M | -44.8% |
| FY2022 | 2022-12-31 | 1.05B | -8.4% |
| FY2021 | 2021-12-31 | 1.15B | — |
Research & Development vs competitors
How DNA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -37.9% is the lowest of 10, against a peer median of +9.2%.
- Research & development amounts to 157.6% of revenue for DNA, versus a peer median of 112.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $446.24M USD | -15.0% | -3.0% | 681.3% | |
| LTM Mar 2026 | $254.4M USD | -28.3% | -3.5% | 284.6% | |
| LTM Sep 2026 | $241.88M USD | -19.7% | +0.6% | 63.8% | |
| LTM Dec 2025 | $223.39M USD | +26.2% | +32.9% | — | |
| LTM Mar 2026 | $222.77M USD | -37.9% | -38.6% | 157.6% | |
| LTM Mar 2026 | $129.68M USD | +5.2% | +71.4% | — | |
| LTM Mar 2026 | $128.82M USD | +9.2% | +14.8% | 161.5% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $101.27M USD | +35.7% | +54.7% | — |
| LTM Mar 2026 | €85.57M EUR | +12.6% | -6.7% | 54.7% | |
| LTM Jun 2026 | $21.15M USD | +13.2% | +8.3% | 10.1% | |
| Peer median (excluding DNA) | — | +9.2% | +8.3% | 112.7% | |
Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 313.84M | 477.71M | 251.46M | 227.04M | 170.16M |
| Cost of Revenue | 129.69M | 204.22M | 54.01M | 38.55M | 31.52M |
| Gross Profit | 184.15M | 273.49M | 197.45M | 188.49M | 138.63M |
| Gross Margin | 58.7% | 57.3% | 78.5% | 83.0% | 81.5% |
| Research & Development | 1.15B | 1.05B | 580.62M | 424.06M | 243.77M |
| Selling, General & Admin | 862.95M | 1.43B | 385.03M | 246.16M | 183.29M |
| Operating Expenses | 2.01B | 2.48B | 1.06B | 748.25M | 453.91M |
| Depreciation & Amortization | 29.08M | 61.63M | 71.55M | 63.02M | 58.99M |
| EBITDA | (1.81B) | (2.06B) | (821.29M) | (484.39M) | (254.61M) |
| EBITDA Margin | -575.7% | -431.2% | -326.6% | -213.3% | -149.6% |
| Operating Income | (1.83B) | (2.21B) | (864.41M) | (559.76M) | (315.28M) |
| Operating Margin | -582.6% | -462.4% | -343.8% | -246.5% | -185.3% |
| Interest Income | 837K | 20.26M | 57.22M | 38.61M | 22.62M |
| Interest Expense | 2.37M | 106K | 93K | 94K | 0 |
| Other Income / Expenses | (9.66M) | 87.55M | (28.53M) | 12.25M | 1.68M |
| Income Before Tax | (1.84B) | (2.12B) | (892.94M) | (547.51M) | (313.6M) |
| Pre-Tax Margin | -585.7% | -444.1% | -355.1% | -241.1% | -184.3% |
| Income Tax Expense | (1.48M) | (15.03M) | (71K) | (479K) | (837K) |
| Net Income | (1.83B) | (2.1B) | (892.87M) | (547.03M) | (312.76M) |
| Net Margin | -583.1% | -440.6% | -355.1% | -240.9% | -183.8% |
| EPS (Basic) | (53.83) | (50.15) | (18.37) | (10.54) | (5.64) |
| EPS (Diluted) | (55.53) | (50.20) | (18.40) | (10.54) | (5.64) |
| Weighted Avg Shares | 32.95M | 41.93M | 48.53M | 51.89M | 55.46M |
| Weighted Avg Shares (Diluted) | 34.01M | 42M | 48.61M | 51.89M | 55.46M |
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
Intrinsic Alpha fair value
Locked
Current Price
$8.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.